This treatment may be given by mouth, or right into your blood through an I.V. (intravenous) line.
Experts are still trying to figure out the best way to use targeted therapy medicines. They're often used one at a time. And if a medicine stops working, another might be tried. Some may be used in combination with a type of immunotherapy medicine.
Some kidney cancer cells are controlled by proteins in the cells, called tyrosine kinases, that help them grow. Some targeted therapies block these proteins so cancer cell growth slows or stops.
Kidney cancer cells also make a protein that fosters the growth of new blood vessels (called angiogenesis). These blood vessels are needed to get nutrients to the cancer cells so they can grow and divide. Blocking this process can keep tumors from growing.
Types of targeted therapy medicine
The two main types of targeted therapy medicines used for kidney cancer are tyrosine kinase inhibitors and monoclonal antibodies. These medicines include angiogenesis inhibitors (bevacizumab and TKIs), mTOR kinase inhibitors, and an HIF2a inhibitor. These are most commonly used:
- Sunitinib (by mouth)
- Sorafenib (by mouth)
- Pazopanib (by mouth)
- Cabozantinib (by mouth)
- Lenvatinib (by mouth)
- Bevacizumab (I.V. infusion)
- Axitinib (by mouth)
- Temsirolimus (I.V. infusion)
- Everolimus (by mouth)
- Tivozanib (by mouth)
- Belzutifan (by mouth)—used specifically for people with von Hippel-Lindau disease and kidney cancer. This is an HIF2a inhibitor.